Особенности и преимущества Ксеникала: Библиография

Библиография

1. Hochuli E., Kupfer E., Maurer R., et al. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini II. Chemistry and structure elucidation. J Antibiot. 1987; 40:1086-1091;
2. Guerciolini R. et al., Mode of action of orlistat. Int J Obesity. 1997; 21 (suppl 3): S12-S23;
3. Weibel EK, Hadvary P Hochuli E, et al. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J Antibiot. 1987; 40: 1081-1085;
4. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994; 56: 82-85;
5. Data on file. Hoffmann-La Roche Ltd., Basel, Switzerland;
6. Howe GR, Aronson KJ, Benito E, et al. The relationship between dietary fat intake and risk of colorectal cancer: evidence from the combined analysis or 13 case-control studies. Cancer Causes Control. 1997; 8: 215-228;
7. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994; 56: 82-85;
8. Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in health human volunteers. J Clin Pharmacol. 1995; 35: 1103-1108;
9. Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in health volunteers. J Clin Pharmacol. 1995; 35: 521-525;
10. Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol. 1996; 36: 1006-1011;
11. Melia AT, Zhi J, Koss-Twardy SG, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol. 1995; 35: 840-843;
12. Melia AT, Mulligan OA, Zhi J. et al., The effect of orlistat on the pharmacokinetics of phenyfoin in healthy volunteers. J Clin Pharmacol. 1996; 36: 654-658;
13. Zhi J, Melia AT, Guerciolini R, et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol. 1996; 36: 659-666;
14. Weber C, Tam YK, Schmidtke-Schrezenmeier G, et al. Effect of the lipase inhibitor orlistat on the pharmacokinetics of the four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol. 1996; 51: 87-90;
15. Melia AT, Mulligan OA, Zhi J. et al., Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers. J Clin Pharmacol. 1996; 36: 352-355;
16. Hartmann D, Gezelhan C, Zuiderwijk et al.,. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol. 1996; 50: 421-424;
17. Ryan DH, Kaiser P, Bray G. et al., Sibutramine: a novel new agent for obesity treatment, Obes Res. 1995; 3(suppl 4): 5535-5595;
18. Guy-Grand B, Crepaldi G, Lefebvre P, et al., International trial of long-term dexfenfluramine in obesity. Lancet. 1989; 2: 1142-1145;
19. Hsieh CJ, Wang PW, Liu RT, ci al. Orlistat for obesity: benefits beyond weight loss. Diabetes Res Clin Pract 2005 Jan; 67 (1): 78-83
20. Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002 Sep; 56 (7): 494-9
21. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000 Sep; 248 (3): 245-54
22. Krempf M, Louvet JP, Allanic H, et al. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes Relat Metab Disord 2003 May; 27 (5): 591-7
23. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281 (3): 235-42
24. Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000 Feb; 9 (2): 160-7
25. Rössner S, Sjöström L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000 Jan; 8 (1): 49-61
26. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998 Jul 18; 352 (9123): 167-72
27. Swinburn BA, Carey D, Hills AP, et al. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab 2005 May; 7 (3): 254-62
28. Bakris G, Calhoun D, Egan B, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002 Nov; 20 (11): 2257-67
29. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 Jan; 27 (1): 155-61
30. Toplak H, Ziegler О, Keller U, et al. X-PFRT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005 Nov; 7 (6): 699-708
31. Curran MP, Scott LJ. Orlistat: a review of its use in the management of patients with obesity. Drugs 2004; 64 (24): 2845-64
32. Derosa G, Cicero AFG, Murdolo G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005 Jan; 7 (1): 47-55
33. Kaya A, Aydin N, Topsever P, et al. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 2004 Dec; 58 (10): 582-7
34. Sari R, Balci MK, Cakir M, et al. Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 2004 May; 30 (2): 159-67
35. Toplak H, Ziegler О, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005 Nov; 7 (6): 699-708
36. Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL-Primary Health Care Trial. Diabetes Obes Metab 2005 Jan; 7 (1): 21-7
37. Golay A, Laurent-Jaccard A, Habieht F, et al. Effect of orlistat in obese patients with binge eating disorder. Obes Res 2005 Oct; 13 (10): 1701-8
38. Sjöström L. Analysis of the XENDOS study (Xenical in the Prevention of Diabetes in Obese Subjects). Endocr Pract 2006 Jan-Feb; 12 Suppl. 1:31-3
39. Torgerson JS, Hauptman J, Boldrin M, et al. Efficacy of orlistat plus lifestyle changes in risk reduction of type 2 diabetes in obese patients with metabolic syndrome: a comparative analysis using National Cholesterol Education Program Adult Treatment Panel III vs European group for the study of insulin resistance criteria [abstract no. 690]. Diabetologia 2004; 47 Suppl. 1: A249
40. DeFronzo R, Sjöström L, Torgerson JS, et al. XENDOS: onset of type 2 diabetes in obese patients with normal glucose tolerance/IGT and metabolic syndrome, [abstract no. 1706-P]. 63rd Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans, LA
41. Rissanen A., Andersen T., et al., Randomized placebo controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet 1998; 352:167-172;
42. Научная монография о препарате Ксеникал.

Предыдущий раздел | В начало

Комментарии